{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"83.3","value":"54.5"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"98.7","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a partial response (PR) or better based on International Myeloma Working Group (IMWG) criteria for RRMM participants and based on Lugano criteria for DLBCL participants. Per IMWG criteria, PR was defined as ≥50% reduction of serum M-protein plus reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h. In addition to these criteria, if present at baseline, a ≥50% reduction in the size (sum of the product of the diameters \\[SPD\\]) of soft tissue plasmacytomas was also required. Per Lugano criteria, PR was defined as ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites, absent/normal, regressed, but no increase in non-measurable lesions, spleen regressed \\>50% in length beyond normal (13 centimeters \\[cm\\]), and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG000","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG001","title":"R/R DLBCL Expansion Part A: GEN3014"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC).","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Expansion Part A: Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}